Reconnect Labs
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://reconnect-labs.com/
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Phase 2
Not yet recruiting
- Conditions
- Posttraumatic Stress Disorder (PTSD)Sleep Disturbances and Insomnia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 24
- Registration Number
- NCT06685965
- Locations
- 🇨🇭
Human Sleep Pharmacology, University of Zurich, Zürich, ZH, Switzerland
Dose-finding PKPD Trial for RE02 in Healthy Subjects
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 4
- Registration Number
- NCT05979727
- Locations
- 🇨🇭
University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland
Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Dimethyltryptamin (DMT) & Harmine
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Reconnect Labs
- Target Recruit Count
- 16
- Registration Number
- NCT05829603
- Locations
- 🇨🇭
University Hospital of Psychiatry Zurich, Zürich, ZH, Switzerland
News
No news found